Tevogen Bio Holdings EBIT

The latest EBIT for TVGN is $-21M as of March 2026. That compares with $-34M in the prior-year period — up 38.7% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Tevogen Bio Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, TVGN's EBIT moved from $-34M to $-21M — a 38.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Tevogen Bio Holdings's operating scale or balance-sheet position.

Against its sector companies, TVGN currently prints $-21M for EBIT, while the sector average sits near $-63M. That is roughly 66.3% above the sector mean. Large gaps often invite a closer look at Tevogen Bio Holdings's growth, margins, and balance sheet.

A EBIT figure of $-21M for TVGN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting TVGN's EBIT ($-21M), review year-over-year change from $-34M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.